We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Daubert v Merrell Dow The Supreme Court Tackles Scientific Evidence in the Courtroom

Jay A. Gold, MD, JD, MPH; Miles J. Zaremski, JD; Elaine Rappaport Lev, JD; Deborah H. Shefrin, JD
JAMA. 1993;270(24):2964-2967. doi:10.1001/jama.1993.03510240076036.
Text Size: A A A
Published online


ON JUNE 28, 1993, the US Supreme Court handed down a decision that, in the words of one commentator, "could affect almost every piece of litigation in the Federal courts from this point forward."1 The decision in Daubert v Merrell Dow Pharmaceuticals2 sets forth criteria that federal courts must follow in admitting scientific evidence or excluding it from consideration by juries. While the decision will not apply directly to state courts, states are likely to look to the High Court for guidance. This article will analyze the decision and discuss its implications for medicine, medical publishing, and expert testimony.

THE CASE  The drug for morning sickness, Bendectin (doxylamine), was driven off the market in 1983 by the pressure of lawsuits asserting that it caused birth defects. Before Bendectin was taken off the market, millions of women had used it.3 Of 30 published epidemiologic studies involving over 130


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.